164 related articles for article (PubMed ID: 36831428)
1. Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature.
Taylor L; Wade PK; Johnson JEC; Aldighieri M; Morlando S; Di Leva G; Kerr ID; Coyle B
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831428
[TBL] [Abstract][Full Text] [Related]
2. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
3. YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells.
Dey A; Robitaille M; Remke M; Maier C; Malhotra A; Gregorieff A; Wrana JL; Taylor MD; Angers S; Kenney AM
Oncogene; 2016 Aug; 35(32):4256-68. PubMed ID: 26725322
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
5. ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma.
Ingram WJ; Crowther LM; Little EB; Freeman R; Harliwong I; Veleva D; Hassall TE; Remke M; Taylor MD; Hallahan AR
Exp Hematol Oncol; 2013 Oct; 2(1):26. PubMed ID: 24219920
[TBL] [Abstract][Full Text] [Related]
6. Overcoming multiple drug resistance mechanisms in medulloblastoma.
Othman RT; Kimishi I; Bradshaw TD; Storer LC; Korshunov A; Pfister SM; Grundy RG; Kerr ID; Coyle B
Acta Neuropathol Commun; 2014 May; 2():57. PubMed ID: 24887326
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma.
Nasir A; Cardall A; Othman RT; Nicolaou N; Lourdusamy A; Linke F; Onion D; Ryzhova M; Cameron H; Valente C; Ritchie A; Korshunov A; Pfister SM; Grabowska AM; Kerr ID; Coyle B
Neurooncol Adv; 2021; 3(1):vdab030. PubMed ID: 33948561
[TBL] [Abstract][Full Text] [Related]
8. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
Zhou L; Picard D; Ra YS; Li M; Northcott PA; Hu Y; Stearns D; Hawkins C; Taylor MD; Rutka J; Der SD; Huang A
Cancer Res; 2010 Oct; 70(20):8199-210. PubMed ID: 20876797
[TBL] [Abstract][Full Text] [Related]
9. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
10. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
11. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
12. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
13. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
14. Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.
Patil S; Sankpal UT; Hurtado M; Bowman WP; Murray J; Borgmann K; Ghorpade A; Sutphin R; Eslin D; Basha R
Gene; 2019 Jul; 705():67-76. PubMed ID: 30991098
[TBL] [Abstract][Full Text] [Related]
15. Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells.
Khoshyomn S; Manske GC; Lew SM; Wald SL; Penar PL
Pediatr Neurosurg; 2000 Sep; 33(3):123-31. PubMed ID: 11096359
[TBL] [Abstract][Full Text] [Related]
16. An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling.
Wijaya J; Vo BT; Liu J; Xu B; Wu G; Wang Y; Peng J; Zhang J; Janke LJ; Orr BA; Yu J; Roussel MF; Schuetz JD
Cancer Res; 2020 Apr; 80(7):1524-1537. PubMed ID: 31948942
[TBL] [Abstract][Full Text] [Related]
17. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
18. [Effects of changwelqing on nuclear translocation of Y-box binding protein-1 and expression of P-glycoprotein in human colon cancer cell line with drug-resistance induced by vincristine].
Xu JH; Deng WL; Fan ZZ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Jul; 30(7):743-7. PubMed ID: 20929136
[TBL] [Abstract][Full Text] [Related]
19. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
Chiu LY; Ko JL; Lee YJ; Yang TY; Tee YT; Sheu GT
Toxicol Lett; 2010 Feb; 192(3):408-18. PubMed ID: 19944135
[TBL] [Abstract][Full Text] [Related]
20. Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma.
Sreenivasan L; Wang H; Yap SQ; Leclair P; Tam A; Lim CJ
Cell Death Dis; 2020 Dec; 11(12):1035. PubMed ID: 33279931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
